Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002944 · ClinicalTrials.gov registry record · Phase 3
Combination Chemotherapy in Treating Children With Progressive Brain Tumors
A Phase 3 study, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 428
- Enrollment target
NCT00002944: Completed Phase 3 study, sponsored by Children's Oncology Group.
NCT00002944 is a Phase 3 study that has completed, run by Children's Oncology Group. The registered enrollment target is 428 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (45% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002944, a Phase 3 study, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 428 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: This randomized phase III trial is studying two different combination chemotherapy regimens and comparing how well they work in treating children with low-grade astrocytomas or other residual tumors of the brain.
Primary Outcome
Compare the event-free survival as a result of treatment with either CV or TPCV
Interventions
- DRUG carboplatin
- DRUG vincristine sulfate
- DRUG lomustine
- DRUG procarbazine hydrochloride
- DRUG thioguanine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 428 participants |
| Start Date | 1997-04 |
| Est. Completion | 2012-04 |
| Phase | Phase 3 |
What the finished NCT00002944 record still lists
NCT00002944 is an interventional study that assigns participants to a tested intervention. The registered 428 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (45% lower).
The record links to 0 conditions, and to 5 interventions - of which carboplatin is the first listed.
NCT00002944 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002944 about?
NCT00002944 is a clinical study titled "Combination Chemotherapy in Treating Children With Progressive Brain Tumors". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: This randomized phase III trial is studying two different combination chemotherapy regimens and comparing how well...
What is the current status of trial NCT00002944?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 428 participants. The study started on 1997-04. Estimated completion is 2012-04.
What interventions are being tested in trial NCT00002944?
The interventions under investigation include: carboplatin (DRUG), vincristine sulfate (DRUG), lomustine (DRUG), procarbazine hydrochloride (DRUG), thioguanine (DRUG).
Who is sponsoring clinical trial NCT00002944?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002944's enrollment target sits among peer trials
428 878th of 2000 higher than 1,121 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05566431 · 428 participants · NA
Benchmark Evidence Led by Latin America: Trial of Intracranial Pressure - Pediatrics
- NCT05646316 · 428 participants · Phase 3
Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer
- NCT05797610 · 428 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
- NCT06073626 · 428 participants · NA
Addressing Genomic Disparities in Cancer Survivors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia